Amazon.com on Track for Record High Close — Data Talk
Amazon.com, Inc. (AMZN) is currently at $189.89, up $0.81 or 0.43%
--Would be new all-time high (Based on available data back to May 15, 1997)
--On pace for its first record close since May 9, 2024, when it closed at $189.50
--Currently up four of the past five days
--Currently up three consecutive days; up 3.87% over this period
--Best three day stretch since the three days ending May 6, 2024, when it rose 5.42%
--Up 7.62% month-to-date; on pace for best month since Feb. 2024, when it rose 13.89%
--Up 24.98% year-to-date
--Up 49.13% from 52 weeks ago (June 26, 2023), when it closed at $127.33
--Would be a new 52-week closing high
--Up 58.81% from its 52-week closing low of $119.57 on Oct. 26, 2023
--Traded as high as $191.00; highest intraday level since May 9, 2024, when it hit $191.70
--Up 1.02% at today's intraday high
--Fifth most active stock in the S&P 500 today
--Fifth most active stock in the Nasdaq 100 today
--Contributed 5.32 points to the DJIA so far today
All data as of 10:31:18 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
June 24, 2024 10:48 ET (14:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks